269 related articles for article (PubMed ID: 26940805)
21. A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.
Bain EE; Apostol G; Sangal RB; Robieson WZ; McNeill DL; Abi-Saab WM; Saltarelli MD
J Clin Psychiatry; 2012 Jun; 73(6):783-9. PubMed ID: 22795204
[TBL] [Abstract][Full Text] [Related]
22. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia.
Arce E; Balice-Gordon R; Duvvuri S; Naylor M; Xie Z; Harel B; Kozak R; Gray DL; DeMartinis N
J Psychopharmacol; 2019 Oct; 33(10):1237-1247. PubMed ID: 31264510
[TBL] [Abstract][Full Text] [Related]
23. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
[TBL] [Abstract][Full Text] [Related]
24. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
Wagg A; Dale M; Tretter R; Stow B; Compion G
Eur Urol; 2013 Jul; 64(1):74-81. PubMed ID: 23332882
[TBL] [Abstract][Full Text] [Related]
25. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.
Hong LE; Thaker GK; McMahon RP; Summerfelt A; Rachbeisel J; Fuller RL; Wonodi I; Buchanan RW; Myers C; Heishman SJ; Yang J; Nye A
Arch Gen Psychiatry; 2011 Dec; 68(12):1195-206. PubMed ID: 21810630
[TBL] [Abstract][Full Text] [Related]
26. Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats.
Hayward A; Adamson L; Neill JC
Eur Neuropsychopharmacol; 2017 Apr; 27(4):325-335. PubMed ID: 28161246
[TBL] [Abstract][Full Text] [Related]
27. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Kreinin A; Bawakny N; Ritsner MS
Clin Schizophr Relat Psychoses; 2017; 10(4):201-210. PubMed ID: 24496044
[TBL] [Abstract][Full Text] [Related]
28. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
29. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
[TBL] [Abstract][Full Text] [Related]
30. Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.
Barch DM; Marder SR; Harms MP; Jarskog LF; Buchanan RW; Cronenwett W; Chen LS; Weiss M; Maguire RP; Pezous N; Feuerbach D; Lopez-Lopez C; Johns DR; Behrje RB; Gomez-Mancilla B
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():66-75. PubMed ID: 27371157
[TBL] [Abstract][Full Text] [Related]
31. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
32. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
[TBL] [Abstract][Full Text] [Related]
34. Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives.
Mucci A; Galderisi S; Green MF; Nuechterlein K; Rucci P; Gibertoni D; Rossi A; Rocca P; Bertolino A; Bucci P; Hellemann G; Spisto M; Palumbo D; Aguglia E; Amodeo G; Amore M; Bellomo A; Brugnoli R; Carpiniello B; Dell'Osso L; Di Fabio F; di Giannantonio M; Di Lorenzo G; Marchesi C; Monteleone P; Montemagni C; Oldani L; Romano R; Roncone R; Stratta P; Tenconi E; Vita A; Zeppegno P; Maj M;
Psychol Med; 2018 Jun; 48(8):1359-1366. PubMed ID: 29017620
[TBL] [Abstract][Full Text] [Related]
35. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.
Kelly DL; McMahon RP; Weiner E; Boggs DL; Dickinson D; Conley RR; Buchanan RW
Schizophr Res; 2008 Aug; 103(1-3):161-8. PubMed ID: 18550339
[TBL] [Abstract][Full Text] [Related]
36. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Lindenmayer JP; Khan A
Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
[TBL] [Abstract][Full Text] [Related]
37. Association of cigarette smoking with cognitive impairment in male patients with chronic schizophrenia.
Wei S; Wang D; Wei G; Wang J; Zhou H; Xu H; Xia L; Tian Y; Dai Q; Zhu R; Wang W; Chen D; Xiu M; Wang L; Zhang XY
Psychopharmacology (Berl); 2020 Nov; 237(11):3409-3416. PubMed ID: 32757027
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R
Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
[TBL] [Abstract][Full Text] [Related]
39. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
[TBL] [Abstract][Full Text] [Related]
40. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
